Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck’s blockbuster Keytruda.